An investigational glypican-3–directed CAR T-cell therapy engineered to express IL-15 and IL-21 produced a complete response lasting at least 1 year in a child with chemotherapy-resistant metastatic hepatoblastoma.
|Articles|February 22, 2021
Pharmacy Times: Week of February 22 Lineup
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.
Advertisement
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week, including:
- A video interview with J. David Robertson, the director of University of Missouri Research Reactor (MURR), on how a new collaboration between MURR and Advanced Accelerator Applications International will help to develop a targeted therapy for certain types of cancerous tumors.
- An article from the recent Society for Advancing Business Editing and Writing Healthcare 2021 virtual symposium, which discusses the main challenges surrounding COVID-19 vaccination—increasing vaccine production and delivery. The presentation noted that the faster people are vaccinated, the fewer opportunities there will be for variant versions of COVID-19 to spread and for more variants to emerge.
Advertisement
Related to this article
Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
EMBER-3 data show switching to the combination at progression nearly doubled PFS versus imlunestrant alone in ESR1-mutated advanced breast cancer.
Target Trial Emulation Finds Limited Survival Benefit With Statins After Colorectal Cancer Treatment
Statin initiation after colorectal cancer treatment was associated with only modest survival differences after investigators accounted for biases that can exaggerate benefits in observational research.
The data help pharmacists predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
This update came with no changes to the safety sections of labeling, with no new signals identified with longer follow-up.
The update shortens required observation to 6 to 8 hours from 22 to 24, easing tarlatamab administration in community settings for ES-SCLC.
Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses
2
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
3
Expert Q&A: Pharmacists Address Pneumococcal Vaccine Hesitancy and Screening Complexity in Transitions of Care
4
Not So Rare After All: Pharmacists Weigh In on Diagnosing and Managing ATTR-CM
5